- Home
- IPM vs IGC Comparison
IPM vs IGC Comparison
Compare IPM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPM
- IGC
- Stock Information
- Founded
- IPM 2005
- IGC 2005
- Country
- IPM United States
- IGC United States
- Employees
- IPM N/A
- IGC N/A
- Industry
- IPM
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- IPM
- IGC Health Care
- Exchange
- IPM NYSE
- IGC Nasdaq
- Market Cap
- IPM 17.6M
- IGC 18.0M
- IPO Year
- IPM N/A
- IGC N/A
- Fundamental
- Price
- IPM $1.80
- IGC $0.29
- Analyst Decision
- IPM Strong Buy
- IGC Strong Buy
- Analyst Count
- IPM 1
- IGC 2
- Target Price
- IPM $6.00
- IGC $3.88
- AVG Volume (30 Days)
- IPM 95.2K
- IGC 231.3K
- Earning Date
- IPM 05-13-2025
- IGC 02-18-2025
- Dividend Yield
- IPM N/A
- IGC N/A
- EPS Growth
- IPM N/A
- IGC N/A
- EPS
- IPM N/A
- IGC N/A
- Revenue
- IPM $1,098,280.00
- IGC $1,236,000.00
- Revenue This Year
- IPM $2,088.06
- IGC N/A
- Revenue Next Year
- IPM $11.00
- IGC $18.34
- P/E Ratio
- IPM N/A
- IGC N/A
- Revenue Growth
- IPM 14.16
- IGC 1.65
- 52 Week Low
- IPM $1.52
- IGC $0.25
- 52 Week High
- IPM $5.50
- IGC $0.63
- Technical
- Relative Strength Index (RSI)
- IPM N/A
- IGC 51.68
- Support Level
- IPM N/A
- IGC $0.27
- Resistance Level
- IPM N/A
- IGC $0.30
- Average True Range (ATR)
- IPM 0.00
- IGC 0.02
- MACD
- IPM 0.00
- IGC 0.00
- Stochastic Oscillator
- IPM 0.00
- IGC 88.00
About IPM INTELLIGENT PROTECTION MANAGEMENT
Intelligent Protection Management Corp is a communications software innovator that powered multimedia social applications.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.